Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

CONCLUSIONS: Improvement in itch and sleep interference due to itch is associated with improvement in the QoL of patients after treatment with lebrikizumab for moderate-to-severe AD.ClinicalTrials.gov registration NCT04146363 (ADvocate1) and NCT04178967 (ADvocate2).PMID:38679419 | DOI:10.1080/09546634.2024.2329240

https://pubmed.ncbi.nlm.nih.gov/38679419/?utm_source=no_user_agent&utm_medium=rs...

Source: Journal of Dermatological Treatment - April 28, 2024 Category: Dermatology Authors: Jennifer Soung Sonja St änder Jan Gutermuth Ignasi Pau-Charles Zach Dawson Fan Emily Yang Luna Sun Evangeline Pierce Hany Elmaraghy Linda Stein-Gold Source Type: research